Risperidone and associated amenorrhea: A report of 5 cases

Journal of Clinical Psychiatry

Volumn 60, Issue 5, 1999, Pages 315-317

  Kim, Yong Ku ^a,b   Kim, Leen ^a   Lee, Min Soo ^a  

^a Korea University College of Medicine   (South Korea)

^b Ansan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; LITHIUM SALT; PROLACTIN; RISPERIDONE; VALPROIC ACID;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; HUMAN; MENSTRUATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY;

EID: 0032993709     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0509     Document Type: Article

References (17)

1. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670
2. 2 and dopamine-2 antagonistic properties. J Pharmacol Exp Ther 1988;244: 685-693
3. Bowden CR, Voina SJ, Woestenboughs R, et al. Stimulation by risperidone of rat prolactin secretion in vivo and cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992;262:699-706
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
5. Risperdal (risperidone). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997:1348-1352
6. Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152:1102-1103
7. Scherzer WJ, McClamrock H. Amenorrhea. In: Berek JS, Adashi EY, Hillard PA, eds. Novak's Gynecology. 12th ed. Baltimore, Md: Williams & Wilkins; 1996:809-832
8. 2 and 5HT2 receptor occupancy induced by risperidone in schizophrenic patients. Presented at the 35th annual meeting of the American College of Neuropharmacology; December 9-13, 1996; San Juan, Puerto Rico
9. Schlegel S, Schlosser R, Hiemke C, et al. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl) 1996;124:285-287
10. Byerly M, Devane L. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-187
11. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51: 388-397
12. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-268
13. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
14. Ghaemi SN, Sachs GS, Baldassano CF, et al. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997; 42:196-199
15. Sommers DK, Snyman JR, Van Wyk M, et al. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Int Clin Psychopharmacol 1997;12:141-145
16. Meltzer HY, Goode DJ, Schyve PM, et al. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550-1555
17. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(suppl 11): 53-56